Abstract
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction. Since Russia eplerenone pharmacoeconomics issues rarely discussed, the analysis of the literature on this topic was performed. 2 studies examined effects of eplerenone in patients with chronic heart failure, 6 — in patients with heart failure after myocardial infarction. The only Russian study on pharmacoeconomics of eplerenone used data from studies in both groups. Due to distinctive methodology, currencies and date of publication, direct comparison of these studies is difficult. However, all studies have demonstrated the pharmacoeconomic benefits of eplerenone in patients with heart failure. A conclusion provided about the need for additional pharmacoeconomic studies of eplerenone in Russian Federation.
Highlights
Eplerenone (Inspra, Pfizer) improves the prognosis of patients with chronic heart failure and heart failure after acute myocardial infarction
All studies have demonstrated the pharmacoeconomic benefits of eplerenone in patients with heart failure
A conclusion provided about the need for additional pharmacoeconomic studies of eplerenone in Russian Federation
Summary
ИМ — инфаркт миокарда, РКИ — рандомизированные клинические испытания, СН — сердечная недостаточность, ФВ ЛЖ — фракция выброса левого желудочка, ХСН — хроническая сердечная недостаточность, QALY — “сохраненные года качественной жизни”; EPHESUS – Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study, EMPHASIS-HF — Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure, PRISMA — Preferred Reporting Items for Systematic reviews and Meta-Analyses. Основу позиции эплеренона в современных рекомендациях [3, 4] определили результаты исследований оригинального прерапата Инспра (Pfizer) в двух крупных рандомизированных клинических испытаниях (РКИ) EPHESUS (Eplerenone PostAcute Myocardial Infarction Heart Failure Efficacy and Survival Study) [5] и EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) [6], а также такие характеристики препарата, как отсутствие влияния на андрогеновые и прогестероновые рецепторы. В этой связи проведен обзор международных и отечественных фармакоэкономических исследований эплеренона при ХСН с целью их систематизации и анализа полученных результатов
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
